1.
CpG DNA as a vaccine adjuvant
by Bode, Christian
Expert review of vaccines, 2011, Vol.10 (4), p.499-511
2.
In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses
by Soifer, Harris S
Nature biotechnology, 2009, Vol.27 (10), p.925-932
3.
First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults
by Luabeya, Angelique Kany Kany
Vaccine, 2015, Vol.33 (33), p.4130-4140
4.
Large intestine-targeted, nanoparticle-releasing oral vaccine to control genitorectal viral infection
by Zhu, Qing
Nature medicine, 2012, Vol.18 (8), p.1291-1296
5.
6.
The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial
by Geldenhuys, Hennie
Vaccine, 2015, Vol.33 (30), p.3592-3599
7.
Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials
by Norrby, Maria
Vaccine, 2017, Vol.35 (12), p.1652-1661
8.
Recent progress concerning CpG DNA and its use as a vaccine adjuvant
by Shirota, Hidekazu Hidekazu
Expert review of vaccines, 2013, Vol.13 (2), p.299-312
9.
10.
Designing an immunocyte-targeting delivery system by use of beta-glucan
by Miyamoto, Noriko
Vaccine, 2018, Vol.36 (1), p.186-189
11.
12.
Recombinant E rns -E2 protein vaccine formulated with MF59 and CPG-ODN promotes T cell immunity against bovine viral diarrhea virus infection
by Wang, Shenghua
Vaccine, 2020, Vol.38 (22), p.3881
13.
14.
Marked enhancement of the immune response to BioThrax® (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers
by Rynkiewicz, Dianna
Vaccine, 2011, Vol.29 (37), p.6313-6320
15.
16.
Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration
by Aguzzi, Adriano
Nature medicine, 2004, Vol.10 (2), p.187-192
17.
Phosphorothioate modification of the TLR9 ligand CpG ODN inhibits poly(I:C)-induced apoptosis of hepatocellular carcinoma by entry blockade
by Zhang, Yuyi
Cancer letters, 2014, Vol.355 (1), p.76-84
18.
CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study
by Cooper, C L
Journal of clinical immunology, 2004, Vol.24 (6), p.693-701
19.
20.
CpG-1826 immunotherapy potentiates chemotherapeutic and anti-tumor immune responses to metronomic cyclophosphamide in a preclinical glioma model
by Jordan, Marie
Cancer letters, 2015, Vol.373 (1), p.88-96
